By Cocer Peptides 
kwanaki 29 da suka gabata
DUKKANIN LABARI DA BAYANIN KYAUTATAWA DA AKE BAYAR A WANNAN SHAFIN KAWAI DOMIN WATSA BAYANI NE DA MANUFOFIN ILIMI.
Kayayyakin da aka bayar akan wannan gidan yanar gizon an yi niyya ne kawai don binciken in vitro. Binciken in vitro (Latin: *a cikin gilashi*, ma'ana a cikin gilashin gilashi) ana gudanar da shi a wajen jikin mutum. Waɗannan samfuran ba magunguna ba ne, Hukumar Abinci da Magunguna ta Amurka (FDA) ba ta amince da su ba, kuma dole ne a yi amfani da su don hanawa, magani, ko warkar da duk wani yanayi na likita, cuta, ko cuta. Doka ta haramta shigar da waɗannan samfuran cikin jikin mutum ko dabba ta kowace hanya.
A duk duniya, kiba ya zama batun kiwon lafiyar jama'a mai tsanani, yana da alaƙa da alaƙa da cututtuka daban-daban kamar cututtukan zuciya da cututtukan zuciya da nau'in ciwon sukari na 2, yana mai da neman ingantattun hanyoyin asara mai mahimmanci na binciken likita. Survodutide, a matsayin sabon magani, ya nuna yuwuwar tasiri a cikin asarar nauyi.
Rahoton da aka ƙayyade na Survodutide
Survodutide bincike ne mai tsayin daka mai dual agonist wanda a lokaci guda ya kai hari ga mai karɓar glucagon-kamar peptide-1 (GLP-1R) da mai karɓar insulinotropic polypeptide mai dogaro da glucose (GIPR). Yana buƙatar gudanarwa sau ɗaya kawai na mako-mako, yana ba wa marasa lafiya ƙarin dacewa da haɓaka riko da jiyya na dogon lokaci.
Kayan aikin Survodutide a cikin Rage nauyi
Sarrafa Karɓar Makamashi
Ciwon Ciki: Bayan kunna GLP-1R da GIPR, Survodutide yana hulɗa tare da tsarin juyayi na tsakiya don daidaita cibiyar kula da ci abinci ta hypothalamic. Kunna GLP-1R yana aiki akan fiber afferent fibers don watsa sigina zuwa tsakiya na arcuate na hypothalamus, yana hana ayyukan furotin agrep (AgRP) neurons, Hakanan yana iya kunna proopiomelanocortin (POMC) neurons, ta haka yana haifar da ma'anar satiety da rage cin abinci. Kunna GIPR na iya haɓaka wannan tasirin hana ci ta hanyoyi iri ɗaya ko na jijiyoyi, ta haka rage sha'awar abinci na jiki kuma saboda haka rage yawan kuzari.
Canza abubuwan zaɓin abinci: A cikin ƙirar hamster na kiba da dyslipidemia wanda aka jawo ta hanyar zaɓin zaɓi na abinci, Survodutide ya yi tasiri na musamman akan abubuwan zaɓin abinci. Idan aka kwatanta da ƙungiyar kulawa, Survodutide ya rage yawan cin abinci mai kitse da ruwa mai fructose a cikin lokacin jiyya na makonni 5, yayin da ba shi da wani tasiri a kan cin abinci na yau da kullum da ruwa na yau da kullum. Wannan sakamako na tsari akan zaɓin abinci yana taimakawa rage cin abinci mai yawan kalori, sarrafa tarin kuzari da yawa a tushen sa da aza harsashi don asarar nauyi.
Daidaita kashe kuɗin makamashi
Inganta mai hadawan abu da iskar shaka: Survodutide yana nuna gagarumin tasiri na tsari akan metabolism na mai. Ta hanyar kunna GLP-1R da GIPR, yana tasiri metabolism mai mai ta hanyar hanyoyin sigina da yawa. Yana inganta lipolysis a cikin adipocytes, yana ƙara sakin fatty acid; Ana kai waɗannan fatty acid ɗin da aka saki zuwa mitochondria don oxidation, don haka ƙara yawan kashe kuzari. Nazarin ya nuna cewa a cikin wani in vitro adipocyte model, bin Survodutide magani, key enzymes da hannu a lipolysis da fatty acid oxidation, irin su hormone-m lipase (HSL), carnitine palmitoyltransferase-1 (CPT-1), yana nuna cewa tsarinsa na aiki a inganta mai hadawan abu da iskar shaka ya ƙunshi daidaita key enzymes a cikin mai metabolism.
Ƙara yawan kashe kuɗi: Baya ga yin aiki kai tsaye akan ƙwayoyin kitse don haɓaka iskar oxygenation mai ƙima, Survodutide kuma na iya haɓaka kashe kuzarin kuzari ta hanyar tasirin tsarin kuzarin kuzari. A cikin gwaje-gwajen dabba, an lura cewa yayin da matakan ayyukan dabbobi ba su canza sosai ba bayan gudanar da Survodutide, ƙimar su na basal ya karu. Wannan shi ne saboda da miyagun ƙwayoyi ta m effects a kan mahara kyallen takarda da gabobin, inganta rayuwa aiki a cikin hanta da kuma kwarangwal tsoka, game da shi ƙara makamashi amfani a cikin wani hutu jihar da kuma cimma wani makamashi rashi, wanda inganta nauyi asara.
Daidaita metabolism metabolism da insulin hankali
Inganta juriya na insulin: Marasa lafiya masu kiba sukan sami juriya na insulin, wanda ke shafar metabolism na makamashi na yau da kullun da amfani. Survodutide yana kunna GLP-1R don tada siginar insulin yayin haɓaka haɓakar insulin, ta haka yana haɓaka jin daɗin jiki ga insulin. A cikin nazarin marasa lafiya da nau'in ciwon sukari na 2, bayan makonni 16 na jiyya na Survodutide, matakan insulin na plasma na plasma da ma'aunin juriya na insulin (HOMA-IR) sun ragu sosai, yana nuna cewa miyagun ƙwayoyi na iya inganta juriya na insulin, yana ba da damar mafi kyawun ɗaukar wayar salula da amfani da glucose, rage jujjuya shi zuwa mai, da kuma taimakawa wajen sarrafa nauyi.
Daidaita matakan glucose na jini: Survodutide's dual receptor agonist aikin yana ba shi fa'ida ta musamman wajen daidaita matakan glucose na jini. GLP-1R Agonism yana haɓaka fitowar insulin yayin da yake hana sakin glucagon, ta haka yana rage matakan glucose na jini. GIPR agonism kuma yana haɓaka haɓakar insulin a ƙarƙashin yanayin physiological. Ta hanyar tasirin synergistic, zai iya mafi kyawun kiyaye matakan glucose na jini. Matsakaicin matakan sukari na jini yana taimakawa rage yunwar da ƙara yawan ajiyar kuzari da ke haifar da canjin sukari na jini, a kaikaice yana yin tasiri mai kyau akan sarrafa nauyi.
Matsayin Survodutide a Rage nauyi
Mahimmancin tasiri na asarar nauyi: A cikin bazuwar, makafi biyu, gwajin gwaji na gwaji na gwaji na Phase 2 wanda ke kula da marasa lafiya, manya 387 masu shekaru 18-75 masu shekaru tare da ma'auni na jiki (BMI) ≥27 kg / m² kuma babu ciwon sukari da aka ba da izini ga ƙungiyoyi biyar, suna karɓar allurar subcutaneous na mako-mako na Survodutide (0.6, 2.4, 3.6, ko 4.8 mg) ko placebo don lokacin jiyya na mako 46. Sakamakon ya nuna cewa a cikin mako na 46, marasa lafiya da aka bi da su tare da 4.8 MG na Survodutide sun sami asarar nauyi na 18.7% idan aka kwatanta da ƙungiyar placebo, tare da bambancin ƙididdiga na rage nauyi. A cikin wani binciken da aka yi niyya ga marasa lafiya da ke da nau'in ciwon sukari na 2 da kiba, jiyya na Survodutide ya haifar da asarar nauyi wanda ya dogara da kashi bayan makonni 16, tare da matsakaicin raguwar 8.7%. Bugu da ƙari, Survodutide a kashi na ≥1.8 MG sau ɗaya a mako yana haifar da asarar nauyi fiye da GLP-1 mai karɓar mai karɓar mai karɓar Semaglutid da aka saba amfani dashi, wanda ya haifar da raguwar nauyin 5.3%.
Bambance-bambancen jinsi da BMI: Ƙarin nazarin ƙananan ƙungiyoyi ya nuna cewa tasirin asarar nauyi na Survodutide ya bambanta a cikin jinsi daban-daban da matakan BMI. A cikin gwajin da aka ambata da aka yi niyya ga marasa lafiya masu kiba, a cikin mako 46, matsakaicin asarar nauyi (17.0%) a cikin rukunin 4.8 mg Survodutide ya kasance mafi girma a cikin mata fiye da maza (11.9%); a cikin ƙungiyoyin BMI daban-daban, marasa lafiya tare da BMI <30 kg / m² yana da kashi mafi girman asarar nauyi (19.1%), amma cikakkiyar ƙimar asarar nauyi ba ta da bambanci sosai a cikin ƙungiyoyin BMI. Wannan yana nuna cewa a cikin aikin asibiti, likitoci za su iya ƙididdige ƙimar asarar nauyi na Survodutide bisa dalilai kamar jinsin haƙuri da BMI.
Rarraba Fat Jiki da Inganta Metabolic
Rage kitsen visceral: Survodutide ba kawai yana rage yawan nauyin jiki ba amma yana da tasiri mai kyau akan rarraba kitsen jiki. Matsanancin tarin kitse na visceral yana da alaƙa da haɓakar cututtukan da ke faruwa na rayuwa daban-daban. A cikin binciken da ya dace, bayan karbar magani na Survodutide na wani lokaci, marasa lafiya sun sami raguwa mai yawa a yankin mai visceral. Wannan shi ne saboda miyagun ƙwayoyi yana inganta rushewa da oxidation na kitsen visceral, inganta metabolism kuma ta haka ne rage haɗarin rayuwa da ke hade da kitsen visceral mai yawa.
Haɓaka rashin daidaituwa na lipid: Marasa kiba sau da yawa suna da rashin daidaituwa na lipid, kamar hypercholesterolemia da hypertriglyceridemia. Survodutide ba wai kawai yana taimakawa wajen asarar nauyi ba amma kuma yana inganta sigogin lipid. A cikin gwaje-gwajen dabbobi, hamsters masu kiba da aka yi amfani da su tare da Survodutide sun nuna raguwa mai yawa a cikin adadin ƙwayar cholesterol cikin jini, tare da raguwar 41% a cikin rukunin Survodutide da raguwar 24% a cikin rukunin semaglutide. An lura da irin wannan sakamakon a cikin gwajin ɗan adam, inda maganin Survodutide ya haifar da raguwa mai yawa a cikin matakan triglyceride. Har ila yau, yana yin nau'i daban-daban na tasiri na tsari akan ƙananan ƙwayar lipoprotein cholesterol (LDL-C) da cholesterol mai yawa na lipoprotein (HDL-C), yana taimakawa wajen gyara dyslipidemia da rage haɗarin cututtukan zuciya.
Tasiri akan abubuwan haɗari na zuciya da jijiyoyin jini
Rage hawan jini: Kiba na ɗaya daga cikin manyan abubuwan haɗari ga hauhawar jini. A cikin gwaje-gwajen asibiti da aka yi niyya ga marasa lafiya masu kiba, bayan makonni 46 na jiyya na Survodutide, duka hawan jini na systolic (SBP) da hawan jini na diastolic (DBP) sun nuna raguwa sosai. Idan aka kwatanta da ƙungiyar placebo, ƙungiyar 4.8 mg Survodutide ta nuna matsakaicin matsakaicin raguwa na 10.2 mmHg a cikin SBP da 4.8 mmHg a cikin DBP. Wannan tasirin rage karfin jini na iya kasancewa da alaƙa da abubuwa da yawa, gami da haɓakar Survodutide na aikin endothelial na jijiyoyin jini, rage ayyukan jijiya mai tausayi, da asarar nauyi, waɗanda ke taimakawa tare da rage haɗarin cututtukan zuciya.
Inganta aikin jijiyoyin jini: Survodutide kuma na iya yin tasirin kariya akan tsarin jijiyoyin jini ta hanyar haɓaka aikin ƙwayoyin jijiyoyi na jijiyoyi. Bayan gudanar da Survodutide, sakin nitric oxide (NO) ta sel endothelial na jijiyoyin jini yana ƙaruwa. NO wani muhimmin vasodilator ne wanda ke fadada hanyoyin jini, yana rage juriya na jijiyoyin jini, kuma yana inganta yanayin jini. Har ila yau, miyagun ƙwayoyi na iya hana amsawar kumburi da damuwa na oxidative, don haka rage lalacewar bangon jijiyoyin jini da kuma ci gaba da kula da lafiyar jijiyoyin jini.
Aikace-aikacen Survodutide a cikin Rage nauyi
Yawan Jama'a
Mutane masu kiba da kiba: Ga masu kiba ko masu kiba tare da BMI ≥ 27 kg/m², Survodutide ya nuna sakamako mai kyau na asarar nauyi. Duk marasa lafiya da ke da kiba mai sauƙi da waɗanda ke da kiba tare da wasu cututtuka na rayuwa irin su nau'in ciwon sukari na 2 ko dyslipidemia na iya amfana daga maganin Survodutide. A cikin gwaje-gwajen asibiti, marasa lafiya masu kiba a cikin ƙungiyoyin shekaru daban-daban (shekaru 18-75) sun nuna kyakkyawar amsa ga Survodutide, yana nuna yawan adadin mutanen da suka cancanta.
Marasa lafiya masu kiba da ke da alaƙa da takamaiman cututtuka: Baya ga yawan kiba na gabaɗaya, Survodutide kuma zaɓi ne na magani don kiba da ke haifar da takamaiman cututtuka, irin su polycystic ovary syndrome (PCOS), inda kiba da rikice-rikicen rayuwa sukan kasance tare.
Don ƙara haɓaka tasirin asarar nauyi da inganta yanayin rayuwa, ana iya amfani da Survodutide tare da sauran hanyoyin magani. Lokacin da aka haɗe shi tare da matakan rayuwa (kulawan abinci da motsa jiki), ana iya samun tasirin haɗin gwiwa. A cikin gwaje-gwaje na asibiti, marasa lafiya da suka karbi maganin Survodutide tare da motsa jiki na yau da kullum da kuma abincin da ya dace sun sami asarar nauyi mafi girma da kuma ƙarin ci gaba mai mahimmanci a cikin alamomi na rayuwa. Bugu da ƙari, ga marasa lafiya da ke da nau'in ciwon sukari na 2 da kiba, ana iya amfani da Survodutide a hade tare da sauran magungunan antidiabetic kamar metformin don sarrafa matakan sukari na jini yayin samun ingantaccen sarrafa nauyi.
Kammalawa
A taƙaice, Survodutide, a matsayin novel dual agonist agonist, yana da amfani ga asarar nauyi. Tsarin aikinta na musamman ba kawai yana rage nauyi yadda yakamata ba har ma yana inganta rarraba kitsen jiki, yana daidaita glucose da metabolism na lipid, kuma yana rage haɗarin cututtukan zuciya.
Sources
[1] Briand F, Augustin R, Bleymehl K, et al. 7279 Survodutide da Semaglutid Dukansu suna haifar da asarar nauyi amma suna Nuna Daban-daban Daban-daban akan fifikon Abinci da Dyslipidemia a cikin Zaɓin Zaɓin Kyauta na Kyautar Abincin Hamster Model [J]. Jaridar Endocrine Society, 2024,8 (Karin_1): bvae134-bvae163.DOI:10.1210/jendso/bvae163.034.
[2] Le Roux C, Steen O, Lucas KJ, et al. Survodutide, mai karɓar glucagon mai karɓa / GLP-1 (GCGR/GLP-1R) agonist dual agonist, yana inganta sigogi na cardiometabolic a cikin manya tare da kiba: nazarin tsarin sarrafa wuribo, gwajin lokaci na 2 bazuwar [J]. Jaridar Zuciya ta Turai, 2024,45(Kari_1):ehae666-ehae2895.DOI:10.1093/eurheartj/ehae666.2895.
[3] Blüher M, Rosenstock J, Hoefler J, et al. Sakamakon amsa-kashi akan HbA (1c) da raguwar nauyin jiki na survodutide, dual glucagon/GLP-1 agonist mai karɓa, idan aka kwatanta da placebo da buɗaɗɗen lakabin semaglutide a cikin mutanen da ke da nau'in ciwon sukari na 2: gwajin gwaji na asibiti [J]. Diabetologia, 2024,67 (3): 470-482.DOI: 10.1007/s00125-023-06053-9.
[4] Mei Z, Pu J, Shao Z. Gwaji biyu na Magunguna don MASH tare da Fibrosis na Hanta [J]. New England Journal of Medicine, 2024,391 (15): 1461-1462.DOI: 10.1056/NEJMc2411003.
[5] Sanyal AJ, Bedossa P, Fraessdorf M, et al. Gwajin Bazuwar Mataki na 2 na Survodutide a cikin MASH da Fibrosis[J]. New England Journal of Medicine, 2024,391 (4): 311-319.DOI: 10.1056/NEJMoa2401755.
[6] Le Roux CW, Steen O, Lucas KJ, et al. Glucagon da GLP-1 mai karɓar agonist dual agonist survodutide don kiba: bazuwar, makafi biyu, mai sarrafa wuribo, gwajin lokaci na neman kashi 2.[J]. Lancet. Ciwon sukari & Endocrinology, 2024. https://api.semanticscholar.org/CorpusID:267503510
[7] Lawitz EJ, Fraessdorf M, Neff GW, et al. OS-119 Survodutide (BI 456906), mai karɓa na glucagon / glucagon-like peptide-1 agonist (GCGR/GLP-1R) dual agonist, a cikin mutanen da ke da ramuwa da raguwar cirrhosis: na kasa da kasa, alamar budewa, gwajin lokaci 1 [J]. Jaridar Hepatology, 2024. https://api.semanticscholar.org/CorpusID:270457365
[8] Le Roux CW, Steen O, Lucas KJ, et al. 6926 Binciken Rukunin Ƙungiya ta Jinsi da Jikin Jiki (BMI) a cikin Mutanen da ke Rayuwa Tare da Kiba/Kiba a cikin Survodutide, Glucagon/GLP-1 Mai karɓar Agonist Dual Agonist, gwaji na II [J]. Jaridar Endocrine Society, 2024,8 (Karin_1): bvae133-bvae163.DOI:10.1210/jendso/bvae163.033.
Samfura akwai don amfani da bincike kawai:
